Profusa secures option to acquire diagnostics firm G3 Vision Labs, contingent on raising $30m and shareholder approval.
Digital health firm Profusa has signed an option agreement to acquire G3 Vision Labs and its subsidiaries, expanding its diagnostics portfolio. The deal hinges on meeting conditions, including raising at least $30m in financing and obtaining shareholder approval.
G3 Vision Labs, which operates in pain management, behavioral health, and addiction treatment, reported estimated 2025 revenue of $111m. The acquisition would add molecular diagnostics, toxicology tests, and autoimmune services to Profusa’s biosensor-focused offerings.
To secure shareholder support, Profusa is offering 201,120 common shares and over 106,000 Series A preferred shares. The deal remains conditional on resolving G3’s indebtedness and other undisclosed terms.